AXQ Capital’s Relay Therapeutics RLAY Stock Holding History

AXQ Capital’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-21,000	Closed	-$174K	–	682
2024 Q1	$174K	Buy	+21,000	New	+$205K	0.04%	537
2023 Q1	–	Sell	-19,304	Closed	-$288K	–	616
2022 Q4	$288K	Buy	+19,304	New	+$369K	0.2%	195

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

AXQ Capital's RLAY Position: Q2 2024 in Review

AXQ Capital sold out of Relay Therapeutics (RLAY) in Q2 2024, closing a stake of 21,000 shares — an estimated $174K sold.

AXQ Capital first reported a position in RLAY in Q4 2022 and held it in 2 quarters. The position peaked at $288K in Q4 2022. 178 funds tracked by Wall St. Rank hold RLAY as of Q2 2024.

AXQ Capital reported no remaining Relay Therapeutics position as of Q2 2024 after selling out during the quarter.
AXQ Capital sold 21,000 Relay Therapeutics shares in Q2 2024, an estimated $174K.
AXQ Capital first reported a position in Relay Therapeutics in Q4 2022 and held it in 2 quarters.
AXQ Capital's Relay Therapeutics position peaked at $288K in Q4 2022.
178 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2024.

Based on AXQ Capital's 13F filing for Q2 2024, filed 13 Aug 2024.